Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the safety, tolerability, efficacy and
pharmacokinetics of BPI-9016M in patients with c-Met-dysregulated advanced NSCLC. Biomarkers
related to the efficacy of BPI-9016M will be investigated.